MiR-150 is a factor of survival in prostate cancer patients

Journal of B.U.ON.

Volumn 20, Issue 1, 2015, Pages 173-179

  Dezhong, Liu ^a   Xiaoyi, Zhang ^a   Xianlian, Long ^a   Hongyan, Zhang ^b   Guohua, Zhao ^a   Bo, Sun ^a   Shenglei, Zou ^a   Lian, Zou ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Beijing Shouer Pharmaceutical Factory   (China)

Author keywords

Biomarker; MiR 150; Prognosis; Prostate cancer

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 150; UNCLASSIFIED DRUG; MIRN150 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; DISEASE COURSE; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTOR; SECONDARY; TIME; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR RECURRENCE; TUMOR VOLUME; UPREGULATION;

CELL LINE, TUMOR; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROPORTIONAL HAZARDS MODELS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84928696136     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010;46:765-781.
2. Lee JT, Lehmann BD, Terrian DM et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008;7:1745-1762.
3. Valencia-Sanchez MA, Liu J, Hannon GJ et al. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006;20:515-524.
4. Katada T, Ishiguro H, Kuwabara Y et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol 2009;34:537-542.
5. Wang M, Yang W, Li M et al. Low expression of miR- 150 in pediatric intestinal Burkitt lymphoma. Exp Mol Pathol 2014;96:261-266.
6. Katada T, Ishiguro H, Kuwabara Y et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol 2009;34:537-542.
7. Amaral FC, Torres N, Saggioro F et al. MicroRNAs differentially expressed in ACTH-secreting pituitary tumors. J Clin Endocrinol Metab 2009;94:320-323.
8. Ma Y, Zhang P, Wang F et al. MiR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 2012;61:1447-1453.
9. Yokobori T, Suzuki S, Tanaka N et al. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci 2013;104:48-54.
10. Chang TC, Yu D, Lee YS et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008;40:43-50.
11. Pecot CV, Calin GA, Coleman RL et al. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011;11:59-67.
12. Soifer HS, Rossi JJ, Saetrom P. MicroRNAs in disease and potential therapeutic applications. Mol Ther 2007;15:2070-2079.
13. Elmen J, Lindow M, Schiitz S et al. LNA-mediated microRNA silencing in non-human primates. Nature 2008;452:896-899.
14. Silvestri P, Di Russo C, Rigattieri S et al. MicroRNAs and ischemic heart disease: Towards a better compre hension of pathogenesis, new diagnostic tools and new therapeutic targets. Recent Pat Cardiovasc Drug Discov 2009;4:109-118.
15. Zhang N, Wei X, Xu L. MiR-150 promotes the proliferation of lung cancer cells by targeting P53. FEBS Lett 2013;587:2346-2351.
16. Yokobori T, Suzuki S, Tanaka N et al. MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1. Cancer Sci 2013;104:48-54.
17. Huang S, Chen Y, Wu W et al. MiR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One 2013;8:e80707.